IRICoR participates for the eighth consecutive year at the 24rd Annual International Partnering Conference BIO-Europe. This conference is held from November 5 to November 7, 2018 at the Bella Center in Copenhagen, Danemark. This industry event aims to create business opportunities between life science players from around the world. It is also an opportunity for companies and institutions to develop partnerships of interest […]
Montreal, October 24, 2018 – IRICoR celebrated, on Monday, 10 years of success in drug discovery and renewed funding from governments. For the occasion, we had a very interesting panel on artificial intelligence and drug discovery which led to a rich discussion between our four panelists: Pierre Côte, Therence Bois, Sébastien Lemieux and Jean-Sébastien Cournoyer. A real success!
Thanks to […]
Laval, October 09, 2018 – Dr. Steven Klein, Vice-President Business Development at IRICoR is a guest speaker today, at the Licensing Executives Society workshop to held at Servier canada inc.
The conference will be entitled “Biotechnology & Pharma Companies: “Facing the challenges in oncology: The North American and French Perspective” »”. Oncology appears today as the most difficult challenging therapeutic area from both scientific […]
On the next October 22, IRICoR invites you to participate in a roundtable featuring four leaders from research, business and industry who will share a new vision for generating the therapeutic solutions of tomorrow.
Speakers
When: Monday, October 22, 2018 at 5 pm
Where: Agora Morris and Rosalind Goodman, Marcelle Coutu Pavilion
This will be followed by a cocktail celebrating 10 years of IRICoR’s […]
Nadine Beauger, Chief Executive Officer of IRICoR, participated, this Monday, to the 2nd edition of the International Congress on Personalized Health Care (ICPHC2018) organized by The Quebec Network for Personalized Health Care (QNPHC) to present the innovative business model of IRICoR at the « Innovative Technologies in “OMICS” Applications » session.
As Université de Montréal’s drug discovery and project […]
Montreal, September 20, 2018 – IRICoR is proud to launch, today with the Oncopole, this new LeadAction-Onco Competition. This joint call for projects, in partnership with the FRQS, is an opportunity for researchers from Quebec and the rest of Canada to accelerate the transformation of their projects in oncology and immuno-oncology into novel therapies […]
Dr. Nadine Beauger, Chief Executive Director and Dr. Steven Klein, Vice President, Business Development at IRCoR, took part in a Q&A session to discuss the key strengths and benefits of IRICoR’s model, its achievements and the partnerships created over the past 10 years, as well as the organization’s vision for the next 5 years, in the August-September 2018 edition of […]
Montreal, July 30, 2018 — IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research), a drug discovery and commercialization cluster, is proud to announce that it has received substantial support from the federal government in the amount of 25 million dollars, as part of the 2018 edition of the Centres of Excellence for Commercialization and Research program […]
Montreal, June 5, 2018 – The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) and its host institution, the Université de Montréal (UdeM) today announced that they have entered into a research collaboration with AbbVie, a global research and development-driven biopharmaceutical company, in order to identify Tumor-Specific Neoantigens (TSNA) based on a novel proprietary platform developed […]
In collaboration with the Québec Government Office in Brussels, the Minister of Economy, Science and Innovation (MESI), organizes an economic mission in research in innovation in the life sciences sector, happening from May 14th to 17th 2018. Nadine Beauger, Chief Executive Officer of IRICoR is a member of the delegation.
This mission will allow the attending Quebec organizations to take […]
